TRIPLN
phase 2drug program · high · Thu Oct 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat cardiometabolic diseases associated with overnutrition and aging, including hypertension, obesity/weight loss, MAFLD/MASH/NAFLD, and metabolic parameters.
Fixed-dose oral combination of L-leucine, metformin, and sildenafil designed to activate AMPK/Sirt1-related energy metabolism pathways; evaluated in randomized controlled clinical trials.
A 12-week randomized, double-blind, placebo-controlled Phase 2 hypertension study evaluating two NS-0200 dose combinations versus placebo with systolic blood pressure as the primary endpoint.
Prior randomized trials reported placebo-adjusted body-weight reductions for leucine/metformin/sildenafil combinations, including -1.99% for Leu/Met/Sil 1.0 and -1.69% for Leu/Met/Sil 4.0 after 24 weeks; a NAFLD study was designed to test reductions in hepatic fat content.
LEUSIX
undisclosedconsumer product · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Provide a leucine and vitamin B6 dietary supplement for metabolic health and weight-management-related use cases.
Dietary supplement combining leucine with vitamin B6/pyridoxine; related studies evaluated leucine/pyridoxine nutraceutical formulations in animal weight-loss and metabolic-syndrome contexts.
Listed by the company as a produced dietary supplement; related published animal studies reported effects of leucine/pyridoxine-containing supplementation on weight and metabolic measures.
In obese dogs, a leucine/pyridoxine nutraceutical supported weight and fat loss comparable to a therapeutic weight-loss diet and greater than placebo. In ponies with equine metabolic syndrome, leucine, pyridoxine, and resveratrol supplementation was associated with body-weight loss and reduced post-prandial insulin concentrations.
Leucine-enabled sirtuin activation platform
exploratoryplatform · high · Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify and develop combinations in which leucine synergizes with natural products or established pharmaceuticals to activate Sirt1/AMPK energy-sensing pathways for cardiometabolic diseases of aging and overnutrition.
Combination biology platform using leucine with sirtuin co-activators, NAD+ precursors, natural compounds, and established drugs; assessed in cell, animal, and human metabolic studies.
Company describes its approach as combining leucine with established natural compounds and pharmaceuticals to synergistically activate the sirtuin pathway; a 2020 publication summarized preclinical and clinical evidence for leucine synergy with sirtuin activators.
Reported findings include increased Sirt1 activity, mitochondrial biogenesis, fatty acid oxidation, lifespan effects in preclinical models, reductions in insulin resistance and cardiometabolic markers, and a 4-week placebo-controlled prediabetes study in which leucine-resveratrol reduced HOMA-IR by 33%.
NS-0100 leucine-metformin combination
undiscloseddrug program · high · Wed Oct 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Improve glycemic control in type 2 diabetes by combining leucine with lower-dose metformin as an adjunct to diet and exercise.
Clinical studies comparing fixed-dose leucine and metformin combinations against standard metformin monotherapy, using blood glucose and HbA1c-related glycemic control endpoints.
Extension protocol NS-0100-01E assessed safety and longer-term effect over an additional 8 weeks after Study NS-01-0100.
